Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience

• DOI: 10.3389/fphar.2024.1449220
• Publication Date: 2024-08-08T04:24:46Z
• Authors: Anna Agnese Stanz...; Claudio Candia; Gerardo Nazzaro; Antonio Caso; Claudia Merola; Lorena Gallotti; Mauro Maniscalco
• Keywords: severe asthma; Pharmacology; 03 medical and health sciences; 0302 clinical medicine; disability; outcome; mepolizumab; biomarkers; Therapeutics. Pharmacology; RM1-950; rehabilitation

Severe eosinophilic asthma (SEA) is often linked to a dysregulation in the Interleukin-(IL)-5 axis. Mepolizumab, humanized monoclonal antibody, reduces eosinophils by directly binging IL-5, potentially restoring homeostatic eosinophil biology, with significant impact on quality of life, acute exacerbations and oral corticosteroids (OCS) elimination SEA patients. While its short- middle-term effects are well described, no study has so far investigated long-lasting The aim our was therefore explore long-term, six-year continuous treatment mepolizumab clinical control remission cohort